All In MedTech

FDA Clearance Tracker · P130022-S069

HFX Dynamis System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 18, 2026

Approved

Time to decision

487 days

Received Apr 18, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P130022-S069
Device name
HFX Dynamis System
Applicant location
Redwood City, CA
Received
Apr 18, 2025
Decided
Aug 18, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P130022

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

This supplement (S069) requested approval for the next generation implantable pulse generator system referred to as the HFX Dynamis System. The HFX Dynamis System is designed to deliver a new stimulation therapy, Bolus 10kHz, and support expanded MRI access to allow for scanning with one broken conductor per percutaneous lead. The key changes approved in this supplement include: a new Implantable Pulse Generator model (IPG3500), an updated Patient Application (PTA10043, v3.0.0), and updated Clinician Programmer Software (v4.0). The device, as modified, will be marketed under the trade name HFX Dynamis System and is indicated as follows:The HFX Dynamis System, HFX iQ System and HFX Trial System are indicated as aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain, and leg pain. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic neuropathy. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of non-surgical refractory back pain (intractable back pain without prior surgery and not a candidate for back surgery). FDA's review of this PMA supplement also included the review and approval of a PCCP: Juno Predetermined Change Control Plan, Rev A., which includes two future firmware modifications: 1. Disabling the 1 MHz ASIC clock while in MRI Mode for the IPG3000 and IPG3500, to reduce RF artifacts in MRI images; and 2. Optimizing power consumption for bolus therapy programs by disabling the ASIC during the bolus Macro Off Time, applicable to the IPG3500 only.

Source documents

Other decisions for Nevro Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.